ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Treatment protocols for small-cell carcinoma of the lung

Treatment protocols for small-cell carcinoma of the lung
Literature review current through: Jan 2024.
This topic last updated: Oct 21, 2022.

INTRODUCTION — The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with small-cell carcinoma of the lung. This is not an exhaustive list; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with small-cell carcinoma of the lung. Additional regimens may be added over time, particularly as treatment for small-cell carcinoma of the lung evolves.

This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with small-cell carcinoma of the lung. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:

(See "Extensive-stage small cell lung cancer: Initial management".)

These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.

REGIMENS

Carboplatin plus etoposide —  (table 1)

Cisplatin (60 mg/m2) plus etoposide —  (table 2)

Cisplatin (80 mg/m2) plus etoposide —  (table 3)

Irinotecan plus cisplatin —  (table 4)

Atezolizumab plus carboplatin and etoposide —  (table 5)

Single-agent topotecan —  (table 6)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Diagnosis and management of lung cancer".)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.

Topic 85693 Version 21.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟